Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy

Journal of Medicinal Chemistry

Volumn 48, Issue 16, 2005, Pages 5321-5328

  Davies, Lawrence C ^a   Friedlos, Frank ^a   Hedley, Douglas ^a   Martin, Jan ^a   Ogilvie, Lesley M ^a   Scanlon, Ian J ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [BIS(2 BROMOETHYL)AMINO] 3,5 DIFLUOROBENZOYL]GLUTAMIC ACID; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; CARBOXYPEPTIDASE G2 ACTIVATOR; ENZYME ACTIVATOR; GLUTAMIC ACID DERIVATIVE; IODOETHYLAMINE DERIVATIVE; MUSTARD GAS DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME SUBSTRATE; ENZYME THERAPY; EVALUATION; FEMALE; FLUORINATION; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUORINE; GAMMA-GLUTAMYL HYDROLASE; HUMANS; MICE; MICE, NUDE; MUSTARD COMPOUNDS; NEOPLASM TRANSPLANTATION; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 23444457117     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0502182     Document Type: Article

References (10)

1. Niculescu-Duvaz, I.; Friedlos, F.; Niculescu-Duvaz, D.; Davies, L.; Springer, C. J. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anti-Cancer Drug Des. 1999, 14, 517-538.
2. Niculescu-Duvaz, I.; Spooner, R.; Marais, R.; Springer, C. J. Gene-directed enzyme prodrug therapy. Bioconjugate Chem. 1998, 9, 4-22.
3. Marais, R.; Spooner, R. A.; Stribbling, S. M.; Light, Y.; Martin, J.; et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotechnol. 1997, 15, 1373-1377.
4. Springer, C. J.; Niculescu-Duvaz, I.; Pedley, R. B. Novel prodrugs of alkylating-agents derived from 2-fluorobenzoic and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. J. Med. Chem. 1994, 37, 2361-2370.
5. Springer, C. J.; Dowell, R.; Burke, P. J.; Hadley, E.; Davies, D. H.; et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: A new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem. 1995, 38, 5051-5065.
6. Friedlos, F.; Davies, L.; Scanlon, I.; Ogilvie, L. M.; Martin, J.; et al. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res. 2002, 62, 1724-1729.
7. Khan, T. H.; Eno-Amooquaye, E. A.; Searle, F.; Browne, P. J.; Osborn, H. M. I.; et al. Novel inhibitors of carboxypeptidase G(2) (CPG(2)): Potential use in antibody-directed enzyme prodrug therapy. J. Med. Chem. 1999, 42, 951-956.
8. Spooner, R. A.; Martin, J.; Friedlos, F.; Marais, R.; Springer, C. J. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther. 2000, 7, 1348-1356.
9. Marais, R.; Spooner, R. A.; Light, Y.; Martin, J.; Springer, C. J. Gene-directed enzyme prodrug therapy with a mustard prodrug/ carboxypeptidase G2 combination. Cancer Res. 1996, 56, 4735-4742.
10. Workman, P.; Twentyman, P.; Balkwill, F.; Balmain, A.; Chaplin, D.; et al. United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br. J. Cancer 1998, 77, 1-10.